Taking the migraine drug topiramate was associated with lower urinary citrate excretion, putting patients at risk for kidney stones, according to a study presented at the National Kidney Foundation 2013 Spring Clinical Meetings. "Hypocitraturia from topiramate is rapid and progressive," researcher Allan Jhagroo said. "This should be taken into account when starting therapy, particularly in patients with a history of urolithiasis or with identifiable lithogenic risk factors."

Related Summaries